Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solutech-TC10 is an oral emulsion formulation of cannabis oil containing delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), developed by New Age Ventures LLC. It is designed to enhance the bioavailability and delivery of cannabinoids compared to traditional oil-based formulations like MCT oil. The formulation utilizes a unique blend of emulsifiers, co-solvents, and antioxidants to create a small molecule delivery system. Clinical studies in healthy adults have demonstrated that Solutech-TC10 provides significantly higher maximum concentrations (Cmax) and faster absorption rates for THC and CBD, while being safe and well-tolerated. It is intended for both therapeutic and recreational applications, offering an oral alternative to smoking.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Solutech-TC10 (New Age Ventures).